Super Religare Laboratories

The British company expects to report "substantial growth" in its food intolerance testing line for full-year 2009, and sales of its microarray-based Genarrayt platform are expected to rise 44 percent to £1.04 million from £72,000 in 2008.

So far this year, Rosetta has found commercialization partners for the diagnostics in the Middle East, Canada, the US, and India.

The arrangement gives Super Religare the rights to distribute the tests in India, Saudi Arabia, Qatar, and the United Arab Emirates.

SRL will distribute Rosetta’ Genomics’ microRNA cancer tests in India, Saudi Arabia, Qatar, and in the UAE.

The service is SRL's first array-based test and could foreshadow the adoption of more array-based diagnostics by the Indian testing giant.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.